Literature DB >> 32347562

Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn's disease.

Marta Vernero1, Davide Giuseppe Ribaldone2, Caterina Cariti3, Simone Ribero3, Sara Susca3, Marco Astegiano4, Paolo Dapavo3.   

Abstract

Entities:  

Year:  2020        PMID： 32347562     DOI： 10.1111/1346-8138.15283

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  4 in total

1.  What is new in dermatotherapy?

Authors:  Anupam Das; Anand Toshniwal; Bhushan Madke
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Jan-Feb       Impact factor: 2.545

Review 2.  Skin manifestations in spondyloarthritis.

Authors:  Katharina Meier; Alexandra Schloegl; Denis Poddubnyy; Kamran Ghoreschi
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-08       Impact factor: 5.346

3.  Multiple Lesions at Different Stages of Pyoderma Gangrenosum in a Crohn's Disease Patient.

Authors:  Heng Zhang; Yifang Sun; Kun Li; Jianzhong Zhang; Xue Chen
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-09

4.  Rapidly Progressing Aseptic Abscesses in a Patient with Ulcerative Colitis.

Authors:  Yoshiharu Yamaguchi; Marie Nakagawa; Shoko Nakagawa; Kazuhiro Nagao; Satoshi Inoue; Tomoya Sugiyama; Shinya Izawa; Yasutaka Hijikata; Masahide Ebi; Yasushi Funaki; Naotaka Ogasawara; Makoto Sasaki; Kunio Kasugai
Journal:  Intern Med       Date:  2020-09-30       Impact factor: 1.271
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.